ArticleLeukemia2020

Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.

Neus Giménez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.